Osteopenia: Clinical Trials

21 trials for Osteopenia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed, 2 terminated, 2 unknown, 1 recruiting. 21 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 121Completed 16, Terminated 2, Unknown 2, Recruiting 1
Phase 23Completed 2, Unknown 1

Follow Osteopenia: new trials by email Literature Review of Osteopenia trials Research Report on Osteopenia

Trials (filtered) newest first · largest first

All 21 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia
veverimer daily, veverimer every other day, Placebo - Osteopenia
Phase 1RecruitingTufts Medical Center602026-04-152026-10-26
CBD in Postmenopausal Women With Osteopenia
CBD, Placebo - Osteopenia
Phase 1TerminatedCanopy Growth Corporation22022-05-012022-09-23
The Effect of Semaglutide on Bone Turnover in Patients With Increased Risk of Bone Fracture
Ozempic, Placebo - Osteopenia
Phase 1 / Phase 2UnknownMorten Frost642021-03-242021-03-30
Effect of a Ghrelin Receptor Agonist on Muscle and Bone
Anamorelin Hydrochloride, Placebo - Sarcopenia, Osteopenia
Phase 1CompletedTufts University322019-12-052024-03-27
Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids
LLP2A-ALENDRONATE, Placebo - Osteopenia, Osteoporosis
Phase 1CompletedNancy E. Lane, MD582016-10-142021-08-06
Melatonin-Micronutrients for Osteopenia Treatment Study
Fiber Pill, Melatonin, Strontium citrate, Vitamins D3 and K2 - Osteoporosis, Osteopenia
Phase 1CompletedDuquesne University232013-08-012018-06-14
Safety Study of an Oral Pro-boneTM, Administered to Post Menopausal Osteopenic Women
Pro-Bone - Osteopenia
Phase 1UnknownOsteoBuild Ltd.202011-09-012011-07-20
The Effect of Chymosin on the Intestinal Absorption of Calcium
Drug A Chymosin, Drug B: Placebo - Osteoporosis, Osteopenia
Phase 1CompletedUniversity of Aarhus1252011-04-012012-03-21
Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men.
RN564 - Osteopenia, Osteoporosis
Phase 1CompletedPfizer682011-04-012024-09-24
Effects of Denosumab on the Pharmacokinetics of Etanercept
Etanercept, Denosumab - Postmenopausal, Osteopenia
Phase 1TerminatedAmgen192011-03-012017-06-20
An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density
Placebo, AMG 167 - Osteopenia
Phase 1CompletedAmgen742010-06-012018-09-06
A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal Japanese and Non-Japanese Women
Romosozumab, Placebo - Osteopenia
Phase 1CompletedAmgen312010-05-032019-07-31
A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass
Romosozumab, Placebo - Osteopenia
Phase 1CompletedAmgen242009-08-182019-07-05
A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women
AMG 167, Placebo - Osteopenia
Phase 1CompletedAmgen692009-05-012010-04-02
Melatonin Osteoporosis Prevention Study
melatonin, sugar pill - Osteoporosis, Osteopenia
Phase 1CompletedDuquesne University192008-09-012012-03-13
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)
Romosozumab, Placebo - Postmenopausal, Osteopenia
Phase 1CompletedAmgen482007-11-142023-08-30
A First-in-human Study Evaluating Romosozumab (AMG 785) in Healthy Men and Postmenopausal Women
Romosozumab, Placebo - Osteopenia
Phase 1CompletedAmgen742006-12-132019-07-05
Isoflavones for Promoting Calcium Absorption and Preventing Bone Loss in Post Menopausal Women
Genistein vs Risedronate - Osteoporosis, Osteopenia
Phase 1CompletedPurdue University232006-01-012018-05-04
Electromagnetic Treatment For Bone Loss After Forearm Fracture
Pulsing electromagnetic field (PEMF) - Bone Disease, Metabolic, Osteopenia
Phase 1 / Phase 2CompletedNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)802003-11-012015-12-23
Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose
risedronate, alendronate - Osteopenia, Osteoporosis
Phase 1CompletedWarner Chilcott322002-11-012013-04-17

Showing 20 of 21. Sign in to see all of them.

Narrower conditions

Bone Diseases, Metabolic (21)  ·  Osteoporosis (10)  ·  Anxiety Disorders (1)  ·  Arthritis (1)  ·  Arthritis, Rheumatoid (1)  ·  Bone Diseases (1)  ·  Bone Resorption (1)  ·  Depression (1)  ·  Hypertension (1)  ·  Osteonecrosis (1)  ·  Sarcopenia (1)

Broader conditions

Metabolic Diseases (21)  ·  Musculoskeletal Diseases (21)  ·  Nutritional and Metabolic Diseases (21)  ·  Bone Diseases (20)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Atrophy (1)  ·  Autoimmune Diseases (1)  ·  Behavior (1)  ·  Behavioral Symptoms (1)  ·  Cardiovascular Diseases (1)  ·  Connective Tissue Diseases (1)  ·  Immune System Diseases (1)  ·  Joint Diseases (1)  ·  Mental Disorders (1)  ·  Muscular Atrophy (1)

Interventions

romosozumab (4)  ·  Melatonin (2)  ·  Risedronic Acid (2)  ·  Alendronate (1)  ·  Denosumab (1)  ·  Dietary Fiber (1)  ·  Etanercept (1)  ·  Lactose (1)  ·  Sugars (1)  ·  Water (1)  ·  anamorelin (1)  ·  microcrystalline cellulose (1)  ·  semaglutide (1)

Sponsors

Amgen (7)  ·  Duquesne University (2)  ·  Baylor College of Medicine (1)  ·  Canopy Growth Corporation (1)  ·  Morten Frost (1)  ·  Nancy E. Lane, MD (1)  ·  National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1)  ·  OsteoBuild Ltd. (1)  ·  Pfizer (1)  ·  Purdue University (1)  ·  Tufts Medical Center (1)  ·  Tufts University (1)  ·  University of Aarhus (1)  ·  Warner Chilcott (1)

Countries

United States (12)  ·  Denmark (2)

Top investigators

Paula A Witt-Enderby, PhD (2)  ·  Amy Sun, MD, PhD (1)  ·  Bess Dawson-Hughes, MD (1)  ·  Boris Kaplan, Prof. (1)  ·  Connie M. Weaver, PhD (1)  ·  Joseph A. Spadaro, PhD (1)  ·  Judith L Balk, MD (1)  ·  Lance Rudolph, MD (1)  ·  Leif Mosekilde, Professor (1)  ·  Mark Swanson, ND (1)  ·  Morten Frost, MD (1)  ·  Nancy E Lane, MD (1)  ·  Steven A. Abrams, MD (1)

Results publications

PMID 15883634, PMID 16076940, PMID 16087995, PMID 22220591, PMID 25271941, PMID 25515208, PMID 26245807, PMID 38737002

NIH funding

P50AT000477 (1), R01AR043740 (1), R21AR074138 (1), R61AR085647 (1)